Analyses of mortality risk in patients with dementia treated with galantamine

    loading  Checking for direct PDF access through Ovid

Abstract

Objective

To analyze mortality data from patients with Alzheimer's disease (AD), Alzheimer's plus cerebrovascular disease (AD + CVD) or vascular dementia (VaD).

Methods

(1) Meta-analysis of mortality data from double-blind, placebo-controlled, randomized trials; and (2) recontact study to collect additional longer term mortality data from previous galantamine trial participants.

Results (meta-analysis)

Across 12 trials (≤6 months duration), there was no increased risk of mortality associated with the use of galantamine (n = 4116) compared with that of placebo (n = 2386) (OR galantamine/placebo: 0.67, 95% CI 0.41–1.10).

Results (recontact study)

Median survival was 79 months for patients with AD (n = 478) and 59 months for patients with AD + CVD (n = 180) or VaD (n = 145). Prolonged galantamine treatment (> vs ≤6 months) was not associated with decreased survival time (75 vs 61 months respectively; P= 0.02). Cox regression analyses were consistent with the Kaplan–Meier analyses.

Conclusions

We found no short-term or longer term evidence of increased risk of mortality associated with the use of galantamine in patients with AD, AD + CVD or VaD.

Related Topics

    loading  Loading Related Articles